Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs
Purpose To compare RA and OA patients' time‐to‐switch after newly initiating treatment with three most commonly used non‐specific (NS)‐NSAIDs and two COX‐2 inhibitors, celecoxib and rofecoxib. Methods Managed care enrollees newly prescribed celecoxib, rofecoxib, ibuprofen, naproxen or diclofena...
Gespeichert in:
| Veröffentlicht in: | Pharmacoepidemiology and drug safety 2004-05, Vol.13 (5), p.277-287 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 287 |
|---|---|
| container_issue | 5 |
| container_start_page | 277 |
| container_title | Pharmacoepidemiology and drug safety |
| container_volume | 13 |
| creator | Zhao, Sean Z. Wentworth, Chuck Burke, Thomas A. Makuch, Robert W. |
| description | Purpose
To compare RA and OA patients' time‐to‐switch after newly initiating treatment with three most commonly used non‐specific (NS)‐NSAIDs and two COX‐2 inhibitors, celecoxib and rofecoxib.
Methods
Managed care enrollees newly prescribed celecoxib, rofecoxib, ibuprofen, naproxen or diclofenac were identified. Time to switch to a different NS‐NSAID or COX‐2 specific inhibitor was determined using time‐to‐event analysis and Cox proportional hazards models were used to estimate the odds ratio (OR) after controlling for potential confounders.
Results
The time to 25% of the cohort switching was longer for rofecoxib and celecoxib (159 and 205 days respectively) compared to the three NS‐NSAIDs (49–78 days). Patients were at the highest risk of switching within the first 100 days of therapy. After adjusting for potential confounding factors, the OR for switching to another NS‐NSAID or COX‐2 specific inhibitor ranged from 1.74 to 2.35 for the three NS‐NSAIDs compared to celecoxib (all comparisons, p |
| doi_str_mv | 10.1002/pds.909 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71909758</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71909758</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4099-58d9df96e35d7d3837495c58a7815f8d4aaec08949b3d51726c1c635b172cf4e3</originalsourceid><addsrcrecordid>eNp10E1PHCEcBnBi2viefoOGUz00Y2EZBjjqbt0ajS9RozfCAuOgO8MITNTP0C9dNrPRU0_8gR9PwgPAN4wOMUKTX72JhwKJDbCNkRAFppR9Wc2UFJxWYgvsxPiEUL4T5SbYwhQTwhjfBn9nYXiE8dUl3bjuEfYqJRu6CFXrx62zXYowgwaGxg6tSt4ZqEJqgksuw85AH5P1n0dDXEVNLx-KCYy91a52GrqucQuXfBifdL4rPu4ubo5OZ3EPfK3VMtr99boL7k5-307_FOeX89Pp0Xmhy9XnKDfC1KKyhBpmCCesFFRTrhjHtOamVMpqxEUpFsRQzCaVxroidJFHXZeW7IIfY24f_MtgY5Kti9oul6qzfoiS4VwlozzDgxHq4GMMtpZ9cK0K7xIjuepd5t5lxll-X0cOi9aaT7cuOoOfI3h1S_v-vxx5NbsZ44pRu1zs24dW4VlWjDAq7y_mcn6Nzo4fTs7kLfkHN1-dew</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71909758</pqid></control><display><type>article</type><title>Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zhao, Sean Z. ; Wentworth, Chuck ; Burke, Thomas A. ; Makuch, Robert W.</creator><creatorcontrib>Zhao, Sean Z. ; Wentworth, Chuck ; Burke, Thomas A. ; Makuch, Robert W.</creatorcontrib><description>Purpose
To compare RA and OA patients' time‐to‐switch after newly initiating treatment with three most commonly used non‐specific (NS)‐NSAIDs and two COX‐2 inhibitors, celecoxib and rofecoxib.
Methods
Managed care enrollees newly prescribed celecoxib, rofecoxib, ibuprofen, naproxen or diclofenac were identified. Time to switch to a different NS‐NSAID or COX‐2 specific inhibitor was determined using time‐to‐event analysis and Cox proportional hazards models were used to estimate the odds ratio (OR) after controlling for potential confounders.
Results
The time to 25% of the cohort switching was longer for rofecoxib and celecoxib (159 and 205 days respectively) compared to the three NS‐NSAIDs (49–78 days). Patients were at the highest risk of switching within the first 100 days of therapy. After adjusting for potential confounding factors, the OR for switching to another NS‐NSAID or COX‐2 specific inhibitor ranged from 1.74 to 2.35 for the three NS‐NSAIDs compared to celecoxib (all comparisons, p < 0.01). Similar findings were obtained when comparing rofecoxib to each of the three NS‐NSAIDS (all comparisons, p < 0.01). When COX‐2 inhibitors combined were compared to NS‐NSAIDS combined, the OR for switching was 1.53 (95% confidence interval=1.42–1.65; p < 0.01) after adjusting for potential confounders.
Conclusions
Patients on the COX‐2 specific inhibitors (celecoxib and rofecoxib) were significantly less likely to switch their therapy than patients on NS‐NSAIDS (ibuprofen, naproxen and diclofenac). These results suggest that COX‐2 specific inhibitors may be a more effective treatment option when compared with NS‐NSAIDs in usual clinical practice. Copyright © 2003 John Wiley & Sons, Ltd.</description><identifier>ISSN: 1053-8569</identifier><identifier>EISSN: 1099-1557</identifier><identifier>DOI: 10.1002/pds.909</identifier><identifier>PMID: 15133778</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Adult ; Anti-Inflammatory Agents, Non-Steroidal - administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Arthritis, Rheumatoid - complications ; Arthritis, Rheumatoid - drug therapy ; Celecoxib ; COX-2 specific inhibitors ; Cyclooxygenase Inhibitors - administration & dosage ; Cyclooxygenase Inhibitors - therapeutic use ; drug utilization ; Female ; Gastrointestinal Diseases - complications ; Humans ; Lactones - administration & dosage ; Lactones - therapeutic use ; Male ; Middle Aged ; NSAIDs ; Osteoarthritis - complications ; Osteoarthritis - drug therapy ; Pharmacoepidemiology ; Proportional Hazards Models ; Pyrazoles ; Sulfonamides - administration & dosage ; Sulfonamides - therapeutic use ; Sulfones ; switching ; Time Factors</subject><ispartof>Pharmacoepidemiology and drug safety, 2004-05, Vol.13 (5), p.277-287</ispartof><rights>Copyright © 2003 John Wiley & Sons, Ltd.</rights><rights>Copyright 2003 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4099-58d9df96e35d7d3837495c58a7815f8d4aaec08949b3d51726c1c635b172cf4e3</citedby><cites>FETCH-LOGICAL-c4099-58d9df96e35d7d3837495c58a7815f8d4aaec08949b3d51726c1c635b172cf4e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpds.909$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpds.909$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15133778$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhao, Sean Z.</creatorcontrib><creatorcontrib>Wentworth, Chuck</creatorcontrib><creatorcontrib>Burke, Thomas A.</creatorcontrib><creatorcontrib>Makuch, Robert W.</creatorcontrib><title>Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs</title><title>Pharmacoepidemiology and drug safety</title><addtitle>Pharmacoepidem. Drug Safe</addtitle><description>Purpose
To compare RA and OA patients' time‐to‐switch after newly initiating treatment with three most commonly used non‐specific (NS)‐NSAIDs and two COX‐2 inhibitors, celecoxib and rofecoxib.
Methods
Managed care enrollees newly prescribed celecoxib, rofecoxib, ibuprofen, naproxen or diclofenac were identified. Time to switch to a different NS‐NSAID or COX‐2 specific inhibitor was determined using time‐to‐event analysis and Cox proportional hazards models were used to estimate the odds ratio (OR) after controlling for potential confounders.
Results
The time to 25% of the cohort switching was longer for rofecoxib and celecoxib (159 and 205 days respectively) compared to the three NS‐NSAIDs (49–78 days). Patients were at the highest risk of switching within the first 100 days of therapy. After adjusting for potential confounding factors, the OR for switching to another NS‐NSAID or COX‐2 specific inhibitor ranged from 1.74 to 2.35 for the three NS‐NSAIDs compared to celecoxib (all comparisons, p < 0.01). Similar findings were obtained when comparing rofecoxib to each of the three NS‐NSAIDS (all comparisons, p < 0.01). When COX‐2 inhibitors combined were compared to NS‐NSAIDS combined, the OR for switching was 1.53 (95% confidence interval=1.42–1.65; p < 0.01) after adjusting for potential confounders.
Conclusions
Patients on the COX‐2 specific inhibitors (celecoxib and rofecoxib) were significantly less likely to switch their therapy than patients on NS‐NSAIDS (ibuprofen, naproxen and diclofenac). These results suggest that COX‐2 specific inhibitors may be a more effective treatment option when compared with NS‐NSAIDs in usual clinical practice. Copyright © 2003 John Wiley & Sons, Ltd.</description><subject>Adult</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Arthritis, Rheumatoid - complications</subject><subject>Arthritis, Rheumatoid - drug therapy</subject><subject>Celecoxib</subject><subject>COX-2 specific inhibitors</subject><subject>Cyclooxygenase Inhibitors - administration & dosage</subject><subject>Cyclooxygenase Inhibitors - therapeutic use</subject><subject>drug utilization</subject><subject>Female</subject><subject>Gastrointestinal Diseases - complications</subject><subject>Humans</subject><subject>Lactones - administration & dosage</subject><subject>Lactones - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>NSAIDs</subject><subject>Osteoarthritis - complications</subject><subject>Osteoarthritis - drug therapy</subject><subject>Pharmacoepidemiology</subject><subject>Proportional Hazards Models</subject><subject>Pyrazoles</subject><subject>Sulfonamides - administration & dosage</subject><subject>Sulfonamides - therapeutic use</subject><subject>Sulfones</subject><subject>switching</subject><subject>Time Factors</subject><issn>1053-8569</issn><issn>1099-1557</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10E1PHCEcBnBi2viefoOGUz00Y2EZBjjqbt0ajS9RozfCAuOgO8MITNTP0C9dNrPRU0_8gR9PwgPAN4wOMUKTX72JhwKJDbCNkRAFppR9Wc2UFJxWYgvsxPiEUL4T5SbYwhQTwhjfBn9nYXiE8dUl3bjuEfYqJRu6CFXrx62zXYowgwaGxg6tSt4ZqEJqgksuw85AH5P1n0dDXEVNLx-KCYy91a52GrqucQuXfBifdL4rPu4ubo5OZ3EPfK3VMtr99boL7k5-307_FOeX89Pp0Xmhy9XnKDfC1KKyhBpmCCesFFRTrhjHtOamVMpqxEUpFsRQzCaVxroidJFHXZeW7IIfY24f_MtgY5Kti9oul6qzfoiS4VwlozzDgxHq4GMMtpZ9cK0K7xIjuepd5t5lxll-X0cOi9aaT7cuOoOfI3h1S_v-vxx5NbsZ44pRu1zs24dW4VlWjDAq7y_mcn6Nzo4fTs7kLfkHN1-dew</recordid><startdate>200405</startdate><enddate>200405</enddate><creator>Zhao, Sean Z.</creator><creator>Wentworth, Chuck</creator><creator>Burke, Thomas A.</creator><creator>Makuch, Robert W.</creator><general>John Wiley & Sons, Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200405</creationdate><title>Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs</title><author>Zhao, Sean Z. ; Wentworth, Chuck ; Burke, Thomas A. ; Makuch, Robert W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4099-58d9df96e35d7d3837495c58a7815f8d4aaec08949b3d51726c1c635b172cf4e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adult</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - administration & dosage</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Arthritis, Rheumatoid - complications</topic><topic>Arthritis, Rheumatoid - drug therapy</topic><topic>Celecoxib</topic><topic>COX-2 specific inhibitors</topic><topic>Cyclooxygenase Inhibitors - administration & dosage</topic><topic>Cyclooxygenase Inhibitors - therapeutic use</topic><topic>drug utilization</topic><topic>Female</topic><topic>Gastrointestinal Diseases - complications</topic><topic>Humans</topic><topic>Lactones - administration & dosage</topic><topic>Lactones - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>NSAIDs</topic><topic>Osteoarthritis - complications</topic><topic>Osteoarthritis - drug therapy</topic><topic>Pharmacoepidemiology</topic><topic>Proportional Hazards Models</topic><topic>Pyrazoles</topic><topic>Sulfonamides - administration & dosage</topic><topic>Sulfonamides - therapeutic use</topic><topic>Sulfones</topic><topic>switching</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhao, Sean Z.</creatorcontrib><creatorcontrib>Wentworth, Chuck</creatorcontrib><creatorcontrib>Burke, Thomas A.</creatorcontrib><creatorcontrib>Makuch, Robert W.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacoepidemiology and drug safety</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhao, Sean Z.</au><au>Wentworth, Chuck</au><au>Burke, Thomas A.</au><au>Makuch, Robert W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs</atitle><jtitle>Pharmacoepidemiology and drug safety</jtitle><addtitle>Pharmacoepidem. Drug Safe</addtitle><date>2004-05</date><risdate>2004</risdate><volume>13</volume><issue>5</issue><spage>277</spage><epage>287</epage><pages>277-287</pages><issn>1053-8569</issn><eissn>1099-1557</eissn><abstract>Purpose
To compare RA and OA patients' time‐to‐switch after newly initiating treatment with three most commonly used non‐specific (NS)‐NSAIDs and two COX‐2 inhibitors, celecoxib and rofecoxib.
Methods
Managed care enrollees newly prescribed celecoxib, rofecoxib, ibuprofen, naproxen or diclofenac were identified. Time to switch to a different NS‐NSAID or COX‐2 specific inhibitor was determined using time‐to‐event analysis and Cox proportional hazards models were used to estimate the odds ratio (OR) after controlling for potential confounders.
Results
The time to 25% of the cohort switching was longer for rofecoxib and celecoxib (159 and 205 days respectively) compared to the three NS‐NSAIDs (49–78 days). Patients were at the highest risk of switching within the first 100 days of therapy. After adjusting for potential confounding factors, the OR for switching to another NS‐NSAID or COX‐2 specific inhibitor ranged from 1.74 to 2.35 for the three NS‐NSAIDs compared to celecoxib (all comparisons, p < 0.01). Similar findings were obtained when comparing rofecoxib to each of the three NS‐NSAIDS (all comparisons, p < 0.01). When COX‐2 inhibitors combined were compared to NS‐NSAIDS combined, the OR for switching was 1.53 (95% confidence interval=1.42–1.65; p < 0.01) after adjusting for potential confounders.
Conclusions
Patients on the COX‐2 specific inhibitors (celecoxib and rofecoxib) were significantly less likely to switch their therapy than patients on NS‐NSAIDS (ibuprofen, naproxen and diclofenac). These results suggest that COX‐2 specific inhibitors may be a more effective treatment option when compared with NS‐NSAIDs in usual clinical practice. Copyright © 2003 John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>15133778</pmid><doi>10.1002/pds.909</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1053-8569 |
| ispartof | Pharmacoepidemiology and drug safety, 2004-05, Vol.13 (5), p.277-287 |
| issn | 1053-8569 1099-1557 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71909758 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Anti-Inflammatory Agents, Non-Steroidal - administration & dosage Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Arthritis, Rheumatoid - complications Arthritis, Rheumatoid - drug therapy Celecoxib COX-2 specific inhibitors Cyclooxygenase Inhibitors - administration & dosage Cyclooxygenase Inhibitors - therapeutic use drug utilization Female Gastrointestinal Diseases - complications Humans Lactones - administration & dosage Lactones - therapeutic use Male Middle Aged NSAIDs Osteoarthritis - complications Osteoarthritis - drug therapy Pharmacoepidemiology Proportional Hazards Models Pyrazoles Sulfonamides - administration & dosage Sulfonamides - therapeutic use Sulfones switching Time Factors |
| title | Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T18%3A02%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20switching%20patterns%20among%20patients%20with%20rheumatoid%20arthritis%20and%20osteoarthritis%20using%20COX-2%20specific%20inhibitors%20and%20non-specific%20NSAIDs&rft.jtitle=Pharmacoepidemiology%20and%20drug%20safety&rft.au=Zhao,%20Sean%20Z.&rft.date=2004-05&rft.volume=13&rft.issue=5&rft.spage=277&rft.epage=287&rft.pages=277-287&rft.issn=1053-8569&rft.eissn=1099-1557&rft_id=info:doi/10.1002/pds.909&rft_dat=%3Cproquest_cross%3E71909758%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71909758&rft_id=info:pmid/15133778&rfr_iscdi=true |